[go: up one dir, main page]

MX2017003464A - Inhibidores de histona desmetilasa. - Google Patents

Inhibidores de histona desmetilasa.

Info

Publication number
MX2017003464A
MX2017003464A MX2017003464A MX2017003464A MX2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
compounds
histone demethylase
useful
Prior art date
Application number
MX2017003464A
Other languages
English (en)
Inventor
Nie Zhe
Alan Stafford Jeffrey
Marvin Veal James
K Chen Young
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2017003464A publication Critical patent/MX2017003464A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona generalmente a composiciones y métodos para tratar cáncer y enfermedades neoplasticas. Se porporcionan en la presente compuestos derivados de imidazol-piridina sustituidos y composiciones farmacéuticas que comprense los compuestos. Los presentes compuestos y composiciones son útiles para la inhibición de enzimas de histonia desmetilasa. Además, los presentes compuestos y composiciones son útiles para el tratamiento de cáncer pancreático, cáncer de próstata, cáncer de seno, cáncer de vejiga, cáncer de pulmón, cáncer gástrico, leucemia y/o melanoma y los similares.
MX2017003464A 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa. MX2017003464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051268P 2014-09-16 2014-09-16
PCT/US2015/050289 WO2016044342A1 (en) 2014-09-16 2015-09-15 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
MX2017003464A true MX2017003464A (es) 2017-07-13

Family

ID=55533770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003464A MX2017003464A (es) 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa.

Country Status (17)

Country Link
US (2) US9676770B2 (es)
EP (1) EP3193881B1 (es)
JP (1) JP6660060B2 (es)
KR (1) KR20170048590A (es)
CN (1) CN107073006A (es)
AU (1) AU2015317904A1 (es)
BR (1) BR112017005128A2 (es)
CA (1) CA2961525A1 (es)
CL (1) CL2017000643A1 (es)
CO (1) CO2017002772A2 (es)
EA (1) EA201790502A1 (es)
EC (1) ECSP17020172A (es)
ES (1) ES2911292T3 (es)
IL (1) IL251103A0 (es)
MX (1) MX2017003464A (es)
SG (1) SG11201702108PA (es)
WO (1) WO2016044342A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
MX2017003464A (es) * 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
TWI824309B (zh) 2015-11-06 2023-12-01 美商英塞特公司 作為PI3K-γ抑制劑之雜環化合物
ES2995198T3 (en) * 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
JP6970680B2 (ja) * 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
BR112020007593A2 (pt) 2017-10-18 2020-09-24 Incyte Corporation derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
EA200300508A1 (ru) 2000-10-26 2004-06-24 Туларик Инк. Противовоспалительные агенты
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2009519998A (ja) 2005-12-19 2009-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノアルコール誘導体の過活動膀胱の治療の為の使用
EP2205589B1 (en) 2007-10-03 2011-03-23 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
ES2444543T3 (es) 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
EA022964B1 (ru) 2010-01-13 2016-03-31 Темперо Фармасьютикалз, Инк. Соединения, ингибирующие ферменты гистондеацетилазы, и фармацевтическая композиция, содержащая данные соединения
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US9896436B2 (en) * 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
BR112017005128A2 (pt) 2018-07-31
WO2016044342A1 (en) 2016-03-24
US9676770B2 (en) 2017-06-13
US10071984B2 (en) 2018-09-11
ES2911292T3 (es) 2022-05-18
ECSP17020172A (es) 2017-05-31
SG11201702108PA (en) 2017-04-27
EP3193881B1 (en) 2022-02-09
JP2017527590A (ja) 2017-09-21
CA2961525A1 (en) 2016-03-24
CN107073006A (zh) 2017-08-18
EP3193881A1 (en) 2017-07-26
EP3193881A4 (en) 2018-02-21
JP6660060B2 (ja) 2020-03-04
EA201790502A1 (ru) 2017-10-31
CO2017002772A2 (es) 2017-06-09
CL2017000643A1 (es) 2017-12-01
IL251103A0 (en) 2017-04-30
US20170240529A1 (en) 2017-08-24
US20160108033A1 (en) 2016-04-21
AU2015317904A1 (en) 2017-04-06
KR20170048590A (ko) 2017-05-08

Similar Documents

Publication Publication Date Title
MX2017003464A (es) Inhibidores de histona desmetilasa.
TW201613882A (en) Histone demethylase inhibitors
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX376207B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX391865B (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX2017003463A (es) Inhibidores de histona desmetilasa.